Developer docs
API playgroundTry for free, no card

Search company profiles

Almeda Pharmaceuticals Ag

Full company profile

uuid00saylj

Namestring
Almeda Pharmaceuticals Ag
Legal namestring
Almeda Pharmaceuticals AG
Websiteurl
almedapharma.ch
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company founded in 2013 and headquartered in Zug, Switzerland. The company distributes branded generic oncology products under the MEDA line (Camptomeda/Irinotecan, Docemeda/Docetaxel, Eloxamada/Oxaliplatin, Fludameda/Fludarabin, Gemcimeda/Gemcitabin, Rubimeda/Epirubicin, Taxomeda/Paclitaxel, Velbimeda/Vinorelbine, and Zolemeda/Zoledronic Acid), and supplies specialty pharmaceuticals across Transplanthology, CNS, Antimicrobic, and food supplement categories. Through 2023-2024 exclusive partnerships with Callion Pharma (rare disease therapies, Cystic Fibrosis) and Galen Pharma (PKU EASY Microtabs Plus for Phenylketonuria), Almeda is extending into branded rare disease products for the CIS region.

The company holds a Swissmedic license for pharmaceutical activities (wholesaler and sales outside Switzerland) and operates a GDP-compliant quality management system. Its go-to-market is B2B channel partner distribution: Almeda acquires exclusive licensing and distribution rights from international manufacturers and supplies hospitals, pharmacies, and wholesalers across 10 CIS countries (Moldova, Ukraine, Armenia, Azerbaijan, Georgia, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, and Kyrgyzstan). Revenue is generated through licensing/royalty arrangements, sale of branded generic products, and market entry services for international pharmaceutical manufacturers seeking CIS access, including regulatory compliance and supply chain management.

The firm's only disclosed executive is CEO Ala Tocarciuc. Almeda is privately held by its founders, with no disclosed venture capital, private equity, or public market backing. No headcount, revenue, or funding figures are publicly available, and the company has no disclosed AI/ML technology stack; its competitive position rests on CIS regulatory expertise, exclusive territorial licenses, and a Swiss regulatory base of operations.

Short descriptiontext

Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company that distributes branded generic oncology drugs and rare disease therapies through exclusive licensing partnerships across 10 CIS countries, serving hospitals, pharmacies, and wholesalers under a Swissmedic license.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals distribution, rare disease therapies, oncology generic medicines, CIS market entry services, pharmaceutical licensing
Industry4 codes
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAL
Generic Hospital & Institutional Products
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceutical Distribution & Licensing
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Distribution Rights
TypeLicensing Royalties
Description

Almeda Pharmaceuticals AG generates revenue through acquiring exclusive licensing rights to distribute pharmaceutical products in the CIS region, including specialty drugs for rare diseases and food supplements.

almedapharma.ch
2Generic Pharmaceutical Products
TypeOne Time License
Description

Sale of generic pharmaceutical products including oncology medications (Irinotecan, Docetaxel, Oxaliplatin, Gemcitabin, Paclitaxel, etc.), specialty pharma, and food supplements.

almedapharma.ch
3Market Entry Services
TypeProfessional Services
Description

Providing comprehensive market entry services in the CIS region, including regulatory compliance, distribution and supply chain management, and market access facilitation for international pharmaceutical manufacturers.

almedapharma.ch
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 9 records shown
1CAMPTOMEDA
Description

Irinotecan - oncology product

almedapharma.ch
+8 more records
Core offering1 text field

Almeda Pharmaceuticals AG is a Swiss specialty pharmaceutical company that acquires exclusive licensing and distribution rights to international pharmaceutical products and distributes them across the CIS region. Its portfolio spans branded generic oncology drugs (the MEDA line), transplanthology, CNS, antimicrobic, and rare disease therapies, complemented by food supplements. The company also provides regulatory, supply-chain, and market-access services to manufacturers seeking entry into Eastern European and Central Asian markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Almeda Pharmaceuticals AG is a Swiss pharmaceutical company founded in 2013, headquartered in Zug, Switzerland, operating as a specialty pharma company focused on oncology, rare diseases, and food supplements. The product portfolio centers on the MEDA product line (Camptomeda, Docemeda, Eloxamada, Fludameda, Gemcimeda, Rubimeda, Taxomeda, Velbimeda, Zolemeda) - branded generic oncology medications covering Irinotecan, Docetaxel, Oxaliplatin, Fludarabin, Gemcitabin, Epirubicin, Paclitaxel, Vinorelbine, and Zoledronic Acid. The company also offers specialty pharma in Transplanthology, CNS, and Antimicrobic categories; rare disease treatments including small molecules, monoclonal antibodies (MAB), and cell therapy; and consumer health products including vitamins, dietary supplements, and foods for special medical purposes. Through partnerships, Almeda distributes licensed products like PKU EASY Microtabs Plus for Phenylketonuria. The company operates primarily in CIS markets (Ukraine, Moldova, Georgia, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, Kyrgyzstan) with a holistic project management approach from product entry to market.

Product and service15 records
1Camptomeda (Irinotecan)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Camptomeda is Almeda's branded generic version of Irinotecan, a topoisomerase inhibitor used in cancer treatment, supplied via the company's CIS region distribution network to healthcare providers.

2Docemeda (Docetaxel)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Docemeda is Almeda's branded generic version of Docetaxel, a chemotherapy agent used for various cancers, supplied through the CIS distribution network.

3Eloxamada (Oxaliplatin)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Eloxamada is Almeda's branded generic version of Oxaliplatin, a platinum-based chemotherapy drug, supplied via the CIS distribution channel.

4Fludameda (Fludarabin)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Fludameda is Almeda's branded generic version of Fludarabin, a purine analog used in chemotherapy, sold through the CIS distribution network.

5Gemcimeda (Gemcitabin)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Gemcimeda is Almeda's branded generic version of Gemcitabin, a nucleoside analog used in pancreatic, lung, and bladder cancer treatment, supplied through CIS distribution.

6Rubimeda (Epirubicin)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Rubimeda is Almeda's branded generic version of Epirubicin, an anthracycline chemotherapy drug, supplied through the CIS distribution network.

7Taxomeda (Paclitaxel)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Taxomeda is Almeda's branded generic version of Paclitaxel, a microtubule-stabilizing agent used in breast, ovarian, and lung cancers, distributed across the CIS region.

8Velbimeda (Vinorelbine)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Velbimeda is Almeda's branded generic version of Vinorelbine, a vinca alkaloid chemotherapy agent, supplied through the CIS distribution network.

9Zolemeda (Zoledronic Acid)
CategorySpecialty Pharma - Oncology
Description

Oncology medication; Zolemeda is Almeda's branded generic version of Zoledronic Acid, a bisphosphonate used to treat bone metastases and hypercalcemia, supplied via CIS distribution.

10PKU EASY Microtabs Plus
CategoryRare Disease Therapy
Description

Phenylalanine-free protein substitute enriched with vitamins, minerals, and essential and non-essential amino acids for individuals with Phenylketonuria (PKU); licensed from Galen Pharma for distribution by Almeda across six CIS markets.

11Specialty Pharma - Transplanthology
CategorySpecialty Pharma - Transplanthology
Description

Specialty pharmaceutical products for transplanthology that support patients undergoing organ transplantation, distributed to healthcare providers across CIS countries.

12Specialty Pharma - CNS
CategorySpecialty Pharma - CNS
Description

Specialty pharmaceutical products addressing central nervous system disorders, distributed to healthcare providers in CIS markets.

13Specialty Pharma - Antimicrobic
CategorySpecialty Pharma - Antimicrobic
Description

Specialty pharmaceutical products with antimicrobial properties distributed to healthcare providers in CIS markets.

14Callion Pharma Rare Disease Therapies (Cystic Fibrosis)
CategoryRare Disease Therapy - Cell/Small Molecule
Description

Innovative rare disease therapies licensed from Callion Pharma (USA) and distributed by Almeda exclusively across the CIS region for Cystic Fibrosis patients.

15Food Supplements (Vitamins, Dietary Supplements, Foods for Special Medical Purposes)
CategoryFood Supplements / Consumer Health
Description

Food supplements encompassing vitamins, dietary supplements, and foods for special medical purposes, supplied to patients, pharmacists, and wholesalers across CIS markets, including through almedamedical.com.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-25
Description

Galen Pharma, a privately-owned pharmaceutical sales and marketing company, signed an exclusive licensing deal with Almeda Pharmaceuticals AG. The agreement provides Almeda Pharma with exclusive rights to license Galen's PKU EASY Microtabs Plus across several markets including Ukraine, Moldova, Georgia, Armenia, Azerbaijan, and Kazakhstan. PKU Easy Microtabs Plus provides a phenylalanine-free protein substitute for individuals with Phenylketonuria, enriched with vitamins, minerals, and amino acids.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-14
Description

Almeda Pharmaceuticals AG, a Swiss pharmaceutical company, and Callion Pharma, a company located in the USA, announced an exclusive partnership for the Commonwealth of Independent States (CIS) region. This collaboration aims to address the unique healthcare needs of rare disease patients, with exclusive distribution of Callion Pharma's innovative rare disease therapies, prioritizing introduction of essential medications to benefit Cystic Fibrosis patients in CIS countries.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Specialty rare disease pharmaceutical company focused on rare diseases including metabolic and genetic disorders. Both companies target rare disease therapeutics (PKU, Cystic Fibrosis), though Sobi is a global developer with proprietary products while Almeda licenses and distributes for partners.

TypeEmerging player
Description

Specialty rare disease division of Recordati focused on metabolic and rare disorders including PKU. Both companies serve the rare disease patient population in CIS and European markets with specialized therapies, though Recordati develops and markets proprietary products.

TypeBroad incumbent
Description

Hungarian-headquartered pharmaceutical company with deep CIS and Russian market presence. Both companies target specialty pharma and generics distribution in CIS markets; Gedeon Richter operates as a vertically integrated manufacturer with established regional scale.

TypeBroad incumbent
Description

European generics manufacturer headquartered in Prague with significant CIS and Eastern European operations. Zentiva's branded generics portfolio and CIS market presence overlap directly with Almeda's oncology and specialty distribution model.

TypeBroad incumbent
Description

Slovenian pharmaceutical manufacturer with a strong CIS and Eastern European generics footprint. KRKA produces oncology and specialty generics similar to Almeda's MEDA line, but operates as an integrated manufacturer rather than a distribution-focused company.

TypeBroad incumbent
Description

Polish pharmaceutical manufacturer with strong presence in CIS markets and Eastern Europe. Both companies focus on generics and specialty pharmaceuticals for the CIS region, though Polpharma is an integrated manufacturer rather than a distribution specialist.

TypeBroad incumbent
Description

MENA-headquartered pharmaceutical company with growing presence in CIS and Eastern European markets. Both companies focus on branded generics and specialty pharmaceuticals for underserved regional markets.

TypeBroad incumbent
Description

Israeli-headquartered global generics leader with significant CIS and Eastern European operations. Teva's branded generics and specialty portfolio overlaps with Almeda's oncology MEDA line, though Teva operates globally with vastly greater scale.

TypeBroad incumbent
Description

European generics and specialty pharmaceutical company with established presence across CIS and Eastern European markets. Both companies operate in branded generics and specialty distribution, though STADA is far larger and serves broader geographies including Western Europe.

10Sandoz
TypeBroad incumbent
Description

Novartis' generics spin-off with global operations including Europe and CIS markets. Both companies distribute generic and specialty pharmaceuticals, though Sandoz operates as a fully integrated global manufacturer-distributor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Almeda Pharmaceuticals Ag

Specialty Pharmaceutical Distribution & Licensingalmedapharma.ch

Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company that distributes branded generic oncology drugs and rare disease therapies through exclusive licensing partnerships across 10 CIS countries, serving hospitals, pharmacies, and wholesalers under a Swissmedic license.

What Almeda Pharmaceuticals Ag does

Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company founded in 2013 and headquartered in Zug, Switzerland. The company distributes branded generic oncology products under the MEDA line (Camptomeda/Irinotecan, Docemeda/Docetaxel, Eloxamada/Oxaliplatin, Fludameda/Fludarabin, Gemcimeda/Gemcitabin, Rubimeda/Epirubicin, Taxomeda/Paclitaxel, Velbimeda/Vinorelbine, and Zolemeda/Zoledronic Acid), and supplies specialty pharmaceuticals across Transplanthology, CNS, Antimicrobic, and food supplement categories. Through 2023-2024 exclusive partnerships with Callion Pharma (rare disease therapies, Cystic Fibrosis) and Galen Pharma (PKU EASY Microtabs Plus for Phenylketonuria), Almeda is extending into branded rare disease products for the CIS region.

The company holds a Swissmedic license for pharmaceutical activities (wholesaler and sales outside Switzerland) and operates a GDP-compliant quality management system. Its go-to-market is B2B channel partner distribution: Almeda acquires exclusive licensing and distribution rights from international manufacturers and supplies hospitals, pharmacies, and wholesalers across 10 CIS countries (Moldova, Ukraine, Armenia, Azerbaijan, Georgia, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, and Kyrgyzstan). Revenue is generated through licensing/royalty arrangements, sale of branded generic products, and market entry services for international pharmaceutical manufacturers seeking CIS access, including regulatory compliance and supply chain management.

The firm's only disclosed executive is CEO Ala Tocarciuc. Almeda is privately held by its founders, with no disclosed venture capital, private equity, or public market backing. No headcount, revenue, or funding figures are publicly available, and the company has no disclosed AI/ML technology stack; its competitive position rests on CIS regulatory expertise, exclusive territorial licenses, and a Swiss regulatory base of operations.

Almeda Pharmaceuticals Ag firmographics

Firmographics
Name
Almeda Pharmaceuticals Ag
Legal name
Almeda Pharmaceuticals AG
Website
https://almedapharma.ch
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company that distributes branded generic oncology drugs and rare disease therapies through exclusive licensing partnerships across 10 CIS countries, serving hospitals, pharmacies, and wholesalers under a Swissmedic license.
Ownership category
akta.pro rank

Almeda Pharmaceuticals Ag industry classification

Industry
Product category
Specialty Pharmaceutical Distribution & Licensing
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAL
Generic Hospital & Institutional Products

Keywords

  • Specialty pharmaceuticals distribution
  • Rare disease therapies
  • Oncology generic medicines
  • CIS market entry services
  • Pharmaceutical licensing

Where Almeda Pharmaceuticals Ag is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Almeda Pharmaceuticals Ag business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Licensing and Distribution Rights: Almeda Pharmaceuticals AG generates revenue through acquiring exclusive licensing rights to distribute pharmaceutical products in the CIS region, including specialty drugs for rare diseases and food supplements.
  2. Generic Pharmaceutical Products: Sale of generic pharmaceutical products including oncology medications (Irinotecan, Docetaxel, Oxaliplatin, Gemcitabin, Paclitaxel, etc.), specialty pharma, and food supplements.
  3. Market Entry Services: Providing comprehensive market entry services in the CIS region, including regulatory compliance, distribution and supply chain management, and market access facilitation for international pharmaceutical manufacturers.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Almeda Pharmaceuticals Ag product offering

Product offering

Core offering

Almeda Pharmaceuticals AG is a Swiss specialty pharmaceutical company that acquires exclusive licensing and distribution rights to international pharmaceutical products and distributes them across the CIS region. Its portfolio spans branded generic oncology drugs (the MEDA line), transplanthology, CNS, antimicrobic, and rare disease therapies, complemented by food supplements. The company also provides regulatory, supply-chain, and market-access services to manufacturers seeking entry into Eastern European and Central Asian markets.

Product overview

Almeda Pharmaceuticals AG is a Swiss pharmaceutical company founded in 2013, headquartered in Zug, Switzerland, operating as a specialty pharma company focused on oncology, rare diseases, and food supplements. The product portfolio centers on the MEDA product line (Camptomeda, Docemeda, Eloxamada, Fludameda, Gemcimeda, Rubimeda, Taxomeda, Velbimeda, Zolemeda) - branded generic oncology medications covering Irinotecan, Docetaxel, Oxaliplatin, Fludarabin, Gemcitabin, Epirubicin, Paclitaxel, Vinorelbine, and Zoledronic Acid. The company also offers specialty pharma in Transplanthology, CNS, and Antimicrobic categories; rare disease treatments including small molecules, monoclonal antibodies (MAB), and cell therapy; and consumer health products including vitamins, dietary supplements, and foods for special medical purposes. Through partnerships, Almeda distributes licensed products like PKU EASY Microtabs Plus for Phenylketonuria. The company operates primarily in CIS markets (Ukraine, Moldova, Georgia, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, Kyrgyzstan) with a holistic project management approach from product entry to market.

Differentiator

Problem solved

Functional benefit

Brands

  • CAMPTOMEDA: Irinotecan - oncology product
  • DOCEMEDA
  • ELOXAMEDA
  • FLUDAMEDA
  • GEMCIMEDA
  • RUBIMEDA
  • TAXOMEDA
  • VELBIMEDA
  • ZOLEMEDA

Products and services

  • Camptomeda (Irinotecan) Oncology medication; Camptomeda is Almeda's branded generic version of Irinotecan, a topoisomerase inhibitor used in cancer treatment, supplied via the company's CIS region distribution network to healthcare providers.
  • Docemeda (Docetaxel) Oncology medication; Docemeda is Almeda's branded generic version of Docetaxel, a chemotherapy agent used for various cancers, supplied through the CIS distribution network.
  • Eloxamada (Oxaliplatin) Oncology medication; Eloxamada is Almeda's branded generic version of Oxaliplatin, a platinum-based chemotherapy drug, supplied via the CIS distribution channel.
  • Fludameda (Fludarabin) Oncology medication; Fludameda is Almeda's branded generic version of Fludarabin, a purine analog used in chemotherapy, sold through the CIS distribution network.
  • Gemcimeda (Gemcitabin) Oncology medication; Gemcimeda is Almeda's branded generic version of Gemcitabin, a nucleoside analog used in pancreatic, lung, and bladder cancer treatment, supplied through CIS distribution.
  • Rubimeda (Epirubicin) Oncology medication; Rubimeda is Almeda's branded generic version of Epirubicin, an anthracycline chemotherapy drug, supplied through the CIS distribution network.
  • Taxomeda (Paclitaxel) Oncology medication; Taxomeda is Almeda's branded generic version of Paclitaxel, a microtubule-stabilizing agent used in breast, ovarian, and lung cancers, distributed across the CIS region.
  • Velbimeda (Vinorelbine) Oncology medication; Velbimeda is Almeda's branded generic version of Vinorelbine, a vinca alkaloid chemotherapy agent, supplied through the CIS distribution network.
  • Zolemeda (Zoledronic Acid) Oncology medication; Zolemeda is Almeda's branded generic version of Zoledronic Acid, a bisphosphonate used to treat bone metastases and hypercalcemia, supplied via CIS distribution.
  • PKU EASY Microtabs Plus Phenylalanine-free protein substitute enriched with vitamins, minerals, and essential and non-essential amino acids for individuals with Phenylketonuria (PKU); licensed from Galen Pharma for distribution by Almeda across six CIS markets.
  • Specialty Pharma - Transplanthology Specialty pharmaceutical products for transplanthology that support patients undergoing organ transplantation, distributed to healthcare providers across CIS countries.
  • Specialty Pharma - CNS Specialty pharmaceutical products addressing central nervous system disorders, distributed to healthcare providers in CIS markets.
  • Specialty Pharma - Antimicrobic Specialty pharmaceutical products with antimicrobial properties distributed to healthcare providers in CIS markets.
  • Callion Pharma Rare Disease Therapies (Cystic Fibrosis) Innovative rare disease therapies licensed from Callion Pharma (USA) and distributed by Almeda exclusively across the CIS region for Cystic Fibrosis patients.
  • Food Supplements (Vitamins, Dietary Supplements, Foods for Special Medical Purposes) Food supplements encompassing vitamins, dietary supplements, and foods for special medical purposes, supplied to patients, pharmacists, and wholesalers across CIS markets, including through almedamedical.com.

Companies that use Almeda Pharmaceuticals Ag

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Almeda Pharmaceuticals Ag technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Almeda Pharmaceuticals Ag partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Galen PharmacoreOEM/ Whitelabel/ Licensing Partner · 25 January 2024Galen Pharma, a privately-owned pharmaceutical sales and marketing company, signed an exclusive licensing deal with Almeda Pharmaceuticals AG. The agreement provides Almeda Pharma with exclusive rights to license Galen's PKU EASY Microtabs Plus across several markets including Ukraine, Moldova, Georgia, Armenia, Azerbaijan, and Kazakhstan. PKU Easy Microtabs Plus provides a phenylalanine-free protein substitute for individuals with Phenylketonuria, enriched with vitamins, minerals, and amino acids.
  • Callion PharmacoreChannel Partner/ Reseller/ Distributor · 14 December 2023Almeda Pharmaceuticals AG, a Swiss pharmaceutical company, and Callion Pharma, a company located in the USA, announced an exclusive partnership for the Commonwealth of Independent States (CIS) region. This collaboration aims to address the unique healthcare needs of rare disease patients, with exclusive distribution of Callion Pharma's innovative rare disease therapies, prioritizing introduction of essential medications to benefit Cystic Fibrosis patients in CIS countries.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Almeda Pharmaceuticals Ag competitors and assessment

Company assessment

Emerging players

  • Swedish Orphan Biovitrum (Sobi): Specialty rare disease pharmaceutical company focused on rare diseases including metabolic and genetic disorders. Both companies target rare disease therapeutics (PKU, Cystic Fibrosis), though Sobi is a global developer with proprietary products while Almeda licenses and distributes for partners.
  • Recordati Rare Diseases (Orphan Europe): Specialty rare disease division of Recordati focused on metabolic and rare disorders including PKU. Both companies serve the rare disease patient population in CIS and European markets with specialized therapies, though Recordati develops and markets proprietary products.

Broad incumbents

  • Gedeon Richter: Hungarian-headquartered pharmaceutical company with deep CIS and Russian market presence. Both companies target specialty pharma and generics distribution in CIS markets; Gedeon Richter operates as a vertically integrated manufacturer with established regional scale.
  • Zentiva: European generics manufacturer headquartered in Prague with significant CIS and Eastern European operations. Zentiva's branded generics portfolio and CIS market presence overlap directly with Almeda's oncology and specialty distribution model.
  • KRKA: Slovenian pharmaceutical manufacturer with a strong CIS and Eastern European generics footprint. KRKA produces oncology and specialty generics similar to Almeda's MEDA line, but operates as an integrated manufacturer rather than a distribution-focused company.
  • Polpharma: Polish pharmaceutical manufacturer with strong presence in CIS markets and Eastern Europe. Both companies focus on generics and specialty pharmaceuticals for the CIS region, though Polpharma is an integrated manufacturer rather than a distribution specialist.
  • Hikma Pharmaceuticals: MENA-headquartered pharmaceutical company with growing presence in CIS and Eastern European markets. Both companies focus on branded generics and specialty pharmaceuticals for underserved regional markets.
  • Teva Pharmaceutical Industries: Israeli-headquartered global generics leader with significant CIS and Eastern European operations. Teva's branded generics and specialty portfolio overlaps with Almeda's oncology MEDA line, though Teva operates globally with vastly greater scale.
  • STADA Arzneimittel AG: European generics and specialty pharmaceutical company with established presence across CIS and Eastern European markets. Both companies operate in branded generics and specialty distribution, though STADA is far larger and serves broader geographies including Western Europe.
  • Sandoz: Novartis' generics spin-off with global operations including Europe and CIS markets. Both companies distribute generic and specialty pharmaceuticals, though Sandoz operates as a fully integrated global manufacturer-distributor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Almeda Pharmaceuticals Ag social profiles

Digital presence

Almeda Pharmaceuticals Ag compliance and trust

Trust signal

Compliance3 records

Almeda Pharmaceuticals Ag financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Almeda Pharmaceuticals Ag leadership team

Management profile

Number of profiles

Profiles1 record

Almeda Pharmaceuticals Ag funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Almeda Pharmaceuticals Ag M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almeda Pharmaceuticals Ag

What does Almeda Pharmaceuticals Ag do?

Almeda Pharmaceuticals AG is a Swiss specialty pharmaceutical company that acquires exclusive licensing and distribution rights to international pharmaceutical products and distributes them across the CIS region. Its portfolio spans branded generic oncology drugs (the MEDA line), transplanthology, CNS, antimicrobic, and rare disease therapies, complemented by food supplements. The company also provides regulatory, supply-chain, and market-access services to manufacturers seeking entry into Eastern European and Central Asian markets.

Is Almeda Pharmaceuticals Ag a public or private company?

Almeda Pharmaceuticals Ag is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Almeda Pharmaceuticals Ag founded?

Almeda Pharmaceuticals Ag was founded in 2013. It employs 1 to 10 people.

Where is Almeda Pharmaceuticals Ag based?

Almeda Pharmaceuticals Ag is headquartered in Zug, Switzerland, in the Europe region.

How does Almeda Pharmaceuticals Ag make money?

Three revenue lines are on record. Licensing and Distribution Rights are the primary driver. The others are generic Pharmaceutical Products and market Entry Services.

Who are Almeda Pharmaceuticals Ag's main competitors?

Emerging players on record are Swedish Orphan Biovitrum (Sobi) and Recordati Rare Diseases (Orphan Europe). Broad incumbents are Gedeon Richter, Zentiva, KRKA, Polpharma, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, STADA Arzneimittel AG and Sandoz.

Does Almeda Pharmaceuticals Ag have an API?

No public API is recorded for Almeda Pharmaceuticals Ag.

What industry is Almeda Pharmaceuticals Ag in?

Almeda Pharmaceuticals Ag's product category is Specialty Pharmaceutical Distribution & Licensing. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales